The Fly

Axsome’s positive data may provide path for earlier sNDA filing, says Ladenburg

After Axsome Therapeutics announced that AXS-05 met the primary and key secondary endpoints in the ACCORD Phase 3 trial, Ladenburg analyst Matthew Kaplan noted that the company is set to discuss the findings with the FDA and said the "positive" data may provide a possible path for an earlier sNDA filing. Kaplan keeps a Biy rating and unchanged $162 price target on Axsome shares, which are up $16.34, or 29%, to $73.16 in afternoon trading.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on AXSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More